title: Response to 'Intermittent androgen blockade should be regarded as standard therapy in prostate cancer'.
authors.forename: Nicolas
authors.initials: N
authors.lastname: André
authors.forename: Eddy
authors.initials: E
authors.lastname: Pasquier
mesh_terms: D000726:Androgen Antagonists / Q000008:administration & dosage* / Q000592:standards*; D000818:Animals; D045744:Cell Line, Tumor; D004334:Drug Administration Schedule; D006801:Humans; D008297:Male; D051379:Mice; D008819:Mice, Nude; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy / Q000473:pathology; D023041:Xenograft Model Antitumor Assays / Q000379:methods
chemical_list: D000726:Androgen Antagonists